Sarah Jaffe

Differential expression of CCR8 in tumors versus normal tissue allows specific depletion of tumor-infiltrating T regulatory cells by GS-1811, a novel Fc-optimized anti-CCR8 antibody

Changyun Hu, D. Wiederschain, M. Gostissa, 2022, Oncoimmunology.

Inhibition of LILRB2 by a Novel Blocking Antibody Designed to Reprogram Immunosuppressive Macrophages to Drive T Cell Activation in Tumors.

D. Wiederschain, Christina Meyer, M. Gostissa, 2023, Molecular cancer therapeutics.